RegulatoryGuideline · final

FDA finalises potency assurance guidance for cellular and gene therapy products

🇺🇸 FDA · Tue 03 Nov 2026

The US regulator has issued final guidance setting out a quality-risk-management approach to potency across the lifecycle of cell and gene therapies, replacing the December 2023 draft.

The US Food and Drug Administration has announced the availability of final guidance titled "Potency Assurance for Cellular and Gene Therapy Products". The notice appeared in the Federal Register on 3 November 2026 (91 FR 69259, Docket No. FDA-2023-D-4299) and finalises a draft of the same title issued on 28 December 2023.

The guidance gives recommendations to help assure the potency of human cellular therapy and gene therapy (CGT) products at every stage of the product lifecycle. FDA recommends a comprehensive approach grounded in quality risk management.

For investigational products, the document describes how sponsors can progressively put a potency assurance strategy in place during development. It also adds considerations for products moving through rapid clinical development, where potency approaches may need to mature quickly.

For licensed products, the guidance describes the requirements for potency assurance, including the testing required for lot release assays. The notice itself is a three-page announcement; the substantive recommendations sit in the guidance document it points to, which the source text does not reproduce.

As general context, FDA guidance documents represent the agency's current thinking and do not in themselves create legally binding requirements, although they are widely used as a benchmark in product development and in discussions with the agency.

What it means for your team

  • CGT sponsors with products in development should compare their current potency strategies against the final text and any changes from the 2023 draft.
  • Teams running rapid clinical development programmes should look at the added considerations for fast-moving products when planning assay development.
  • Quality and CMC teams for licensed CGT products should review how their lot release assays align with the described potency testing requirements.
  • A quality-risk-management basis means potency assurance is expected to be documented and justified as part of the overall control strategy.

Official guideline text: FDA ↗

Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.

More Regulatory All →